Full history for every metric is available with a Kvantra account
Longboard Pharmaceuticals, Inc. (LBPH)
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -57 | -87 | |||||
| Net profit | $m | - | - | -14 | -28 | -43 | -54 | -76 |
| EPS reported | $ | -2.39 | -2.24 | |||||
| Operating cashflow per share | $ | -2.24 | -2.24 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -2.24 | -2.24 | |||||
| Free cash flow | $m | -51 | -66 | |||||
| Net debt | $m | -48 | -288 | |||||
| Book value equity | $m | 41 | - | |||||
| Book value per share | $ | 1.80 | - | |||||
| Number of shares | m | 22.73 | 38.96 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 3.35 | 33.31 | |||||
| P/S LTM | x | 0.00 | 292,745.11 | |||||
| P/FCF LTM | x | -2.69 | -35.52 | |||||
| EV/EBITDA LTM | x | -2.17 | -23.48 | |||||
| EV/Sales LTM | x | 0.00 | 256,689.36 | |||||
| Earnings Yield LTM | % | -39.71% | -3.99% | |||||
| FCF Yield | % | -37.12% | -2.82% | |||||
| Quality | ||||||||
| ROE | % | -132.99% | -106.30% | |||||
| ROIC | % | -137.11% | -137.11% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -107.09 | -17.66 | |||||
| Net Debt/EBITDA | x | 0.24 | 0.24 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -35.39% | -12.32% | |||||
| Net debt/Equity | x | -1.19 | - | |||||
| Gross debt/equity | x | 0.01 | - | |||||
Company overview
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm committed to advancing innovative treatments for neurological conditions. Its primary drug candidate, LP352, is currently progressing through a Phase 1b/2a clinical trial, aimed at managing seizures associated with developmental and epileptic encephalopathies. The company also boasts preclinical pipeline candidates, LP659 and LP143, designed to tackle a range of neurological diseases. Incorporated in 2020, the company, formerly known as Arena Neuroscience, Inc., adopted its current name, Longboard Pharmaceuticals, Inc., in October 2020. Its corporate headquarters are situated in La Jolla, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Longboard Pharmaceuticals, Inc. (LBPH)
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm committed to advancing innovative treatments for neurological conditions. Its primary drug candidate, LP352, is currently progressing through a Phase 1b/2a clinical trial, aimed at managing seizures associated with developmental and epileptic encephalopathies. The company also boasts preclinical pipeline candidates, LP659 and LP143, designed to tackle a range of neurological diseases. Incorporated in 2020, the company, formerly known as Arena Neuroscience, Inc., adopted its current name, Longboard Pharmaceuticals, Inc., in October 2020. Its corporate headquarters are situated in La Jolla, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free